Haryana suspends 966 drug sale licences and 12 manufacturing licences after FDA inspections uncover irregularities, counterfeit medicines and substandard drugs.
Haryana’s Health Department has intensified its crackdown on counterfeit and substandard medicines to protect public health. Health Minister Arti Singh Rao said the state government is committed to ensuring that citizens have access to genuine, safe and quality medicines. Between April 1 and September 30, 2026, the Food and Drugs Administration (FDA) inspected 13,590 drug sale units and 423 manufacturing units across the state.
Following these inspections, authorities suspended 966 drug sale licences and 12 manufacturing and blood centre licences after identifying regulatory violations. Additionally, 15 licences were cancelled completely, while five others faced partial cancellation.
The action reflects the state government’s stricter approach towards preventing the manufacture and distribution of counterfeit medicines. Haryana drug licence suspensions have become a major part of the FDA’s enforcement drive to strengthen medicine quality and regulatory compliance.
FDA Inspects More Than 14,000 Drug and Manufacturing Units
According to a spokesperson of the Food and Drugs Administration Department, the inspection campaign was carried out under the directions of Health Minister Arti Singh Rao.
During the six-month enforcement period, FDA teams inspected 13,590 retail and wholesale drug sale establishments along with 423 manufacturing units. The inspections focused on identifying violations of drug regulations and preventing the circulation of unsafe or counterfeit medicines.
As a result, 966 drug sale licences and 12 manufacturing or blood centre licences were suspended. The department also cancelled 15 licences entirely and partially cancelled five more.
2,389 Medicine Samples Collected for Quality Testing
To improve quality monitoring, the department collected 2,389 medicine samples between April and September 2026. Out of these, 2,189 samples have undergone testing.
The test results revealed that 11 samples failed to meet the prescribed quality standards and were classified as substandard medicines.
The department is also taking legal action against businesses and individuals found violating drug regulations. Prosecution proceedings were initiated in 64 cases during the reporting period.
Meanwhile, courts disposed of 15 previously pending cases. Eight resulted in convictions, while seven ended in acquittals. A total of 462 cases are still pending before various courts.
also read:- CM Nayab Singh Saini Backs ‘Save Democracy, Remove…
376 Joint Raids Conducted Against Illegal Activities
The FDA also stepped up coordination with the police to strengthen enforcement against illegal drug-related activities.
During the six-month period, police and FDA officials jointly conducted 376 raids. These operations resulted in the registration of two FIRs under the Narcotic Drugs and Psychotropic Substances (NDPS) Act and four FIRs under the Medical Termination of Pregnancy (MTP) Act.
The department said these coordinated operations are aimed at identifying illegal activities and ensuring compliance with the applicable laws.
Fake Mounjaro Injections Worth Rs 70 Lakh Seized
Highlighting some of the major enforcement operations, the department revealed that an FDA team seized counterfeit Mounjaro injections worth approximately Rs 70 lakh in April 2026.
Mounjaro is a prescription medicine used in the treatment of type 2 diabetes and is also associated with weight management.
In another major operation in July 2026, the FDA team in Gurugram uncovered an interstate racket involved in manufacturing and selling counterfeit Telma-AM tablets, which are used to manage high blood pressure.
The department also reported a significant seizure in Faridabad on July 28, 2026. Acting on a complaint, an FDA team confiscated a large consignment of counterfeit propylene glycol.
These operations highlight the department’s efforts to prevent fake pharmaceutical products and potentially unsafe ingredients from entering the supply chain.
More Than 2,600 Drug Sale Licences Issued
Alongside enforcement activities, the department continued working to improve the state’s pharmaceutical and healthcare infrastructure.
During the same period, the FDA issued 2,675 retail and wholesale drug sale licences and 20 manufacturing licences. Additionally, 14 medical institutions received recognition.
The department also upgraded two manufacturing units to World Health Organization Good Manufacturing Practices (WHO-GMP) standards. The move is intended to encourage better manufacturing practices and strengthen quality standards in the pharmaceutical sector.
Arti Singh Rao Announces Zero-Tolerance Policy Against Fake Medicines
Health Minister Arti Singh Rao reiterated that the Haryana government would maintain a zero-tolerance approach towards individuals and organisations involved in activities that threaten public health.
She said the government would not compromise on the quality and safety of medicines supplied to citizens. Strict action will continue against those involved in manufacturing, distributing or selling counterfeit and substandard pharmaceutical products.
The minister further emphasised that access to genuine and high-quality medicines remains a top priority for the state government.
With thousands of inspections, licence suspensions, sample testing and coordinated raids, the Haryana drug licence suspensions and enforcement campaign underline the state’s focus on strengthening pharmaceutical regulation. The FDA is expected to continue its monitoring and action against violations to ensure safer medicines for people across Haryana.
For More Hindi News: http://newz24india.com